Fgfr3 inhibitor compounds
AssigneeEli Lilly and Company
InventorsAdedoyin David ABRAHAM, Desta Doro BUME, Kevin Ronald CONDROSKI, Robert Alan HAZLITT, Timothy Scott KERCHER, Andrew Terrance METCALF, Kaveri Balan URKALAN, Shane Michael WALLS, Andrew Karl DILGER
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.
Claims45
-38. (canceled)
A method of preparing 4-[4-[3-Chloro-4-[1-(5-fluoro-2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-carbonitrile,
- or a pharmaceutically acceptable salt thereof, the method comprising:
- combining 2-[3-Chloro-6-[5-methyl-1-(4-piperidyl)triazol-4-yl]pyrazolo[1,5-a]pyridin-4-yl]oxy-2-(5-fluoro-2-pyridyl)ethanol. HCl,
- a base, and BrCN.
Dependencies are inferred from the claim text.